CHEPLAPHARM is a family-owned pharmaceutical company, headquartered in Germany. We offer our branded products on a global level.
By focusing on an internationally oriented Buy and Build Strategy, we generate annually increasing growth rates. The close collaboration with our business partners and our international subsidiaries allows CHEPLAPHARM to successfully realize its corporate strategy.
Pharma manager Kurt Teubner establishes CHEPLAPHARM in Freiburg, Germany. The company’s name originates from one of the first products in our portfolio: CHEPLAREN®.
The BRAUN family acquires the business with an annual turnover of 600k EURO. The firm’s headquarter is relocated to Mesekenhagen close to the Baltic Sea.
Sebastian F. Braun succeeds as Chief Executive Officer (CEO) of CHEPLAPHARM.
Strategy realignment expressed by the phrase Specialty pharma meets M&A competence.
The products Caye® and Talidat® are acquired from Medopharm and Merck Gruppe.
Acquisition of ALDACTONE®, LANITOP® and ISOMONAT® in Austria from F. Hoffmann-La Roche Basel.
In April, CHEPLAPHARM takes over Ky-Cor F Dragees, Ky-Cor Novo film-coated tablets and Ky- Thermopack from Merck-Gruppe.
CHEPLAPHARM achieves an annual turnover of 3 million EURO, thus doubles the previous year’s result.
Takeover of Aponal® in Germany from F. Hoffmann-La Roche Basel.
In May, CHEPLAPHARM purchases Aquaphor® from Eli Lilly.
In June, CHEPLAPHARM obtains the rights for Gelusil Lac® from the globally operating pharmaceutical manufacturer Johnson & Johnson.
CHEPLAPHARM acquires the traditional Hamburg-based company Walter Ritter GmbH & Co. KG. Consequently, the product portfolio expands with the integration of ice sprays applied especially in the treatment of sports injuries.
The generated sales of nearly 8 million EURO exceed all expectations. So far, this has been the most striking increase in turnover, thus the most successful fiscal year in CHEPLAPHARM’s history.
CHEPLAPHARM continues its growth strategy. Six additional products are integrated into the portfolio: the PC 30® product line from Terra Bio Chemie GmbH, Baldrian Dispert®, one of the most famous German Baldrian brands, applied for sedation and in insomnia treatment, from Vemedia Manufacturing BV, the mineral supplements CalciAPS D3, Magnesium Tonil® Mono as well as Magnesium Tonil® plus Vitamin E from ProStrakan and the pharmaceutical product Apsomol® N from Dr. Willmar Schwabe GmbH & Co. KG, Karlsruhe, Germany.
September - With the acquisition of DISTRANEURIN®/HEMINEVRIN® from the Swedish-British pharmaceutical company AstraZeneca, CHEPLAPHARM expands its presence in numerous European countries. The product generates revenues in the double-digit million range and is a crucial milestone for further internationalization projects of the company.
In July, CHEPLAPHARM attains the rights for a range of products of long-established company Klosterfrau GmbH: Bactisubtil® complex, Enelbin® Paste, Eryfer® 100 and Eryfer® comp as well as Thüringer Kräutertinkturen. By means of this acquisition, CHEPLAPHARM further diversifies its portfolio.
Through our successful merger and acquisition strategy, CHEPLAPHARM has achieved annual double-digit growth rates since 2003. Our export ratio accounts for more than 50 percent.
100 percent takeover of company shares of the in Werne-based Sanavita Pharmaceuticals.
In March, CHEPLAPHARM inaugurates its new logistics center in Neukenkirchen close to Greifswald.
With the takeover of VESANOID® and ROHYPNOL® from F. Hoffmann-La Roche Basel in December, CHEPLAPHARM further maintains its internationalization strategy. Consequently, we further strengthen our position as provider of branded niche products and expand our territorial presence in more than 100 countries worldwide.
Bianca Y. Juha, sister of CEO Sebastian F. Braun, assumes the position of Chief Scientific Officer (CSO).
In September, CHEPLAPHARM acquires Reisegold®, applied in the treatment of travel sickness, as well as Halbmond® tablets for the short-term treatment of insomnia for the German market from Teva GmbH.
Along with its subsidiaries, CHEPLAPHARM attains an annual turnover of 60 million EURO. Moreover, the number of employees increases to more than 70, thus CHEPLAPHARM contributes significantly to the regional development.
The takeover of all company shares from New York-based Glenwood LLC and the purchase of the US-rights for the urology product POTABA® in January represents another Milestone for CHEPLAPHARM. This acquisition is a decisive step towards the further expansion and internationalization of our branded niche products.
CHEPLAPHARM acquires the worldwide rights for POTABA®.
With more than 25 years of experience in the pharmaceutical business, Edeltraud Lafer joins CHEPLAPHARM as Chief Operating Officer (COO) and perfectly complements the management team.
Especially our European presence is notably reinforced by acquiring the UDCA products DEURSIL®/URSOLVAN® and a number of well-established OTC products from Sanofi.
At the end of the year, CHEPLAPHARM opens the doors to its representative and modern office facilities located in the business park of the Hanseatic town of Greifswald. The well-being and the related intensification of teamwork of our currently 74 employees is thus ensured.
At the beginning of the year, CHEPLAPHARM purchases the logistics center from RIEMSER Arzneimittel GmbH in Greifswald.
In January, we expand our product portfolio in Italy by acquiring the product Streptosil® from Boehringer Ingelheim. Also, CHEPLAPHARM secures the German-wide rights for the antihypertensive agents Dopegyt® and Pertenso®, the painkiller Octadon® and the product Cotazym®, applied against digestive disorders, from UCB Pharma GmbH.
In November, CHEPLAPHARM strengthens its presence on the Italian market by the successful acquisition of the prescription drug ALDACTONE® from Sanofi. Thereby, we repeatedly reinforce our international growth strategy.
At the very beginning of the year, CHEPLAPHARM takes over the product rights for ANEXATE® from F. Hoffmann-La Roche Basel. The acquisition of the product ANEXATE® allows CHEPLAPHARM to create strategically important synergies with ROHYPNOL®. This product has already been acquired in 2012, consequently, ANEXATE® perfectly supplements CHEPLAPHARM’s product portfolio in the field of sedatives. The share of exports is thus increased to approximately 80 percent.
End of September, contracts for the worldwide Rights of the Antiadipositum XENICAL® and the Betablocker DILATREND® have been signed. The contract for XENICAL® came into immediate force with day of signature on September 30th. The completion of the contract for DILATREND®, in short: the closing will take place beginning of January 2017. This transaction, worth of EURO 340 million the most significant one since CHEPLAPHARM was established and it is the largest privately owned investment in the Mecklenburg-Vorpommern region.
CHEPLAPHARM concludes with an annual turnover of 121 million EURO, making it one of the largest medium-sized pharmaceutical companies within Germany. The number of employees increases to 120.
The Closing for DILATREND® was completed in mid-January.
Based on a marketing and distribution agreement with Orexigen Therapeutics Ltd., CHEPLAPHARM markets the product MYSIMBA® in Germany, France and Austria from August 2017. This prescription drug perfectly complements the anti-obesity drug XENICAL®, which was acquired in 2016.
September - More than 150 employees from twelve different nations are currently working at CHEPLAPHARM. The company thus makes an important contribution to strengthening the economic power in the region and securing valuable jobs in Mecklenburg-Vorpommern.
Per 01.12.2017, CHEPLAPHARM includes the OTC product range Calcivit D®/Calcivit D® Forte of the German generics company Hexal AG in its portfolio.
With annual sales of 223 million euros, CHEPLAPHARM achieved another significant increase in sales in 2017.
The Closing for the antiviral agent CYMEVENE® took place on 02.01.2018 with F. Hoffmann-La Roche Ltd.
Per 03.01.2018, CHEPLAPHARM takes over the products KONAKION® MM, LARIAM® and INHIBACE®/Plus from F. Hoffmann-La Roche Ltd. Thus, CHEPLAPHARM continues its expansion course.
CHEPLAPHARM further enhances its portfolio in the Cardiology area. Bristol-Myers Squibb’s product SOTALEX®/SOTACOR® has both beta-blocking and antiarrhythmic properties and is thus unique. In addition, the newly acquired product now further promotes the naturally existing synergies between CHEPLAPHARM's already successfully implemented Cardiology preparations.
By acquiring the worldwide rights (except USA) for the product VISUDYNE® of the Swiss Novartis Pharma AG by 15.02.2018, CHEPLAPHARM is now active in the Ophthalmology Area.
Since its foundation, CHEPLAPHARM has pursued a successful and sustainable growth strategy. As this development continues in 2018, the CHEPLAPHARM team already consists of 200 employees by June.